Protease Inhibitors as Promising Weapons against COVID-19: Focus on Repurposing of Drugs used to Treat HIV and HCV Infections

Author(s): Luciana Jesus da Costa, Matheus Mendonça Pereira, Lívia de Souza Ramos, Thaís Pereira de Mello, Laura Nunes Silva, Marta Helena Branquinha, André Luis Souza dos Santos*

Journal Name: Current Topics in Medicinal Chemistry

Volume 21 , Issue 16 , 2021

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


As a part of the efforts to quickly develop pharmaceutical treatments for COVID-19 through repurposing existing drugs, some researchers around the world have combined the recently released crystal structure of SARS-CoV-2 Mpro in complex with a covalently bonded inhibitor with virtual screening procedures employing molecular docking approaches. In this context, protease inhibitors (PIs) clinically available and currently used to treat infectious diseases, particularly viral ones, are relevant sources of promising drug candidates to inhibit the SARS-CoV-2 Mpro, a key viral enzyme involved in crucial events during its life cycle. In the present perspective, we summarized the published studies showing the promising use of HIV and HCV PIs as potential repurposing drugs against the SARS-CoV-2 Mpro.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 30 June, 2021
Page: [1429 - 1438]
Pages: 10
DOI: 10.2174/1568026621666210701093407
Price: $65

Article Metrics

PDF: 113